Pharmaceutical News

RSS

InterveXion receives federal grants for development of drug therapies to treat methamphetamine users

A University of Arkansas for Medical Sciences BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction.

12 Feb 2015

Specific combinations of therapies kill cancer cells, reduce tumors

Controlling the time and sequence of cancer therapies may hold the key to unlocking better outcomes for patients with aggressive cancers, according to research published today.

12 Feb 2015

Diabetes medication can help white blood cells fight bacterial infections

Pioglitazone, a medication approved for treatment of type 2 diabetes, can help bypass genetic defects in chronic granulomatous disease to help white blood cells fight bacterial infections, according to researchers at National Jewish Health.

12 Feb 2015

Retigabine drug shows promise in protecting the brain against effects of ischemic stroke

Retigabine, a drug approved to treat epilepsy, protected the brain against the effects of ischemic stroke in a study conducted at The University of Texas Health Science Center at San Antonio.

12 Feb 2015

Opioid withdrawal in Ontario newborns increases 15-fold

The number of newborns suffering from opioid withdrawal increased 15-fold in Ontario over 20 years, according to research published today in CMAJ Open.

12 Feb 2015

TINA.org objects to proposed class-action settlement regarding Wellesse glucosamine supplement

Continuing its efforts to fight for settlements that are fair to consumers and mandate real changes in deceptive marketing, advocacy group truthinadvertising.org (TINA.org) has filed an objection in a proposed class-action settlement involving the brand-name glucosamine supplement, Wellesse®. Sold at retailers nationwide, the supplement is advertised as a joint pain remedy to ease pain and even rebuild cartilage.

12 Feb 2015

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin.

11 Feb 2015

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Amgen announced today that the Cellular, Tissue and Gene Therapies Advisory Committee and the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration will jointly review the Company's Biologics License Application (BLA) for talimogene laherparepvec.

11 Feb 2015

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

Cumberland Pharmaceuticals Inc. today announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD).

11 Feb 2015

ADDF, Pfizer's CTI collaborate to advance development of new drugs for Alzheimer's disease

The Alzheimer's Drug Discovery Foundation and Pfizer's Centers for Therapeutic Innovation announced today a collaboration designed to advance the development of new small-molecule drugs for Alzheimer's disease and related dementias. As part of the first-of-its kind collaboration in Alzheimer's, the ADDF and CTI will jointly invest in translational research projects, with a focus on novel Alzheimer's drug targets.

11 Feb 2015

Carma Laboratories' NEW Carmex Cold Sore Treatment named 2015 'Product of the Year' winner

Carma Laboratories, Inc., the manufacturer of Carmex lip balm products, is pleased to announce that its NEW Carmex Cold Sore Treatment has been named the 2015 "Product of the Year" winner in the Specialty Skin Treatment category by Product of the Year USA – the nation's largest consumer survey on product innovation.

11 Feb 2015

Oncolytics' REOLYSIN receives FDA Orphan Drug Designation for treatment of ovarian cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian cancer.

11 Feb 2015

ATA recommends daily serving of iodine in multivitamin/mineral supplements for pregnant, breastfeeding women

The American Thyroid Association has championed the effort to include a daily serving of iodine in multivitamin/mineral supplements intended for pregnant and breastfeeding women, and it applauds the new guidelines released by the U.S. Council for Responsible Nutrition advising manufacturers to include 150 micrograms of iodine to these daily supplements.

11 Feb 2015

Researchers close to novel therapy to treat levodopa-induced dyskinesia

Involuntary dyskinetic movements induced by treatment with levodopa (L-dopa) are a common problem for people with Parkinson's disease. Now, however, researchers at Karolinska Institutet and Lund University in Sweden seem to be close to a novel therapy to this distressing side effect.

11 Feb 2015

OSU researchers discover impact of antibiotics on microorganisms that live in animal's gut

Researchers at Oregon State University have discovered that antibiotics have an impact on the microorganisms that live in an animal's gut that's more broad and complex than previously known.

11 Feb 2015

Study shows low-dose oral iron supplementation after blood donation reduces hemoglobin recovery time

Among blood donors with normal hemoglobin levels, low-dose oral iron supplementation, compared with no supplementation, reduced the time to recovery of the postdonation decrease in hemoglobin concentration in donors with low or higher levels of a marker of overall iron storage (ferritin), according to a study in the February 10 issue of JAMA.

11 Feb 2015

Researchers suggest significant relationship between cannabis use and mania symptoms

Researchers from the University of Warwick have found evidence to suggest a significant relationship between cannabis use and the onset and exacerbation of mania symptoms.

11 Feb 2015

Experimental Ebola virus medication shows promise in monkeys

An experimental medication that targets a protein in Ebola virus called VP24 protected 75% of a group of monkeys that were studied from Ebola virus infection, according to new research conducted by the U.S. Army, in collaboration with Sarepta Therapeutics, Inc.

10 Feb 2015

ISG Health creates new algae-based nutraceutical products

International Sustainability Group, Inc. an innovative green technology company is pleased to announce that its wholly owned subsidiary ISG Health created its new algae based product line, being branded under the name AlgaeUP.

10 Feb 2015

Pfenex, Hospira sign agreement to develop and commercialize LUCENTIS biosimilar

Pfenex Inc., a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's LUCENTIS (ranibizumab injection).

10 Feb 2015

Pharmaceutical News

InterveXion receives federal grants for development of drug therapies to treat methamphetamine users

Specific combinations of therapies kill cancer cells, reduce tumors

Diabetes medication can help white blood cells fight bacterial infections

Retigabine drug shows promise in protecting the brain against effects of ischemic stroke

Opioid withdrawal in Ontario newborns increases 15-fold

TINA.org objects to proposed class-action settlement regarding Wellesse glucosamine supplement

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

ADDF, Pfizer's CTI collaborate to advance development of new drugs for Alzheimer's disease

Carma Laboratories' NEW Carmex Cold Sore Treatment named 2015 'Product of the Year' winner

Oncolytics' REOLYSIN receives FDA Orphan Drug Designation for treatment of ovarian cancer

ATA recommends daily serving of iodine in multivitamin/mineral supplements for pregnant, breastfeeding women

Researchers close to novel therapy to treat levodopa-induced dyskinesia

OSU researchers discover impact of antibiotics on microorganisms that live in animal's gut

Study shows low-dose oral iron supplementation after blood donation reduces hemoglobin recovery time

Researchers suggest significant relationship between cannabis use and mania symptoms

Experimental Ebola virus medication shows promise in monkeys

ISG Health creates new algae-based nutraceutical products

Pfenex, Hospira sign agreement to develop and commercialize LUCENTIS biosimilar

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News